ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions
  • Abstract Number: 1776

    Preclinical Development of a Novel TL1A-Targeting Antibody with Extended Half-life and Low Immunogenicity Risk for the Treatment of Inflammatory Diseases
  • Abstract Number: 1777

    Granzyme B as a regulator of interferon alpha production in cutaneous lupus erythematosus
  • Abstract Number: 1778

    Towards an Earlier and Accurate Diagnosis of Connective Tissue Disease-related Interstitial Lung Disease: TGFB Isoform Genes as Upcoming Biomarkers
  • Abstract Number: 1779

    Citrullinated and Malondialdehyde-Acetaldehyde Modified Fibrinogen Activates Macrophages and Induces Inflammatory Responses in Coronary Endothelium
  • Abstract Number: 1780

    Modeling Osteoarthritis Knee Joint in a Compartmentalized Microfluidic System using IPSC-derived Sensory Neurons and human Synovial Fibroblasts
  • Abstract Number: 1781

    Specific gut microbiome remodeling occurs after induction of OA via DMM surgery compared to sham surgery
  • Abstract Number: 1782

    Mapping The Synovial Innervation Of The Human Knee Joint
  • Abstract Number: 1783

    Nerve Growth Factor Causes Sensitization, Nociceptor Sprouting, Synovitis, And Osteophyte Formation In Naïve Murine Joints
  • Abstract Number: 1784

    Multimodal Preclinical Screening Of Glucocorticoid-Induced Disruption Of Bone Remodeling In Rat
  • Abstract Number: 1785

    Soluble CD14 Amplifies Chondrocyte Inflammatory Responses to Lipopolysaccharide and Is Targetable by Anti-CD14 Therapy
  • Abstract Number: 1786

    SEV-101, A Regenerative Exosome Therapeutic for the Treatment of Osteoarthritis
  • Abstract Number: 1787

    Spatial and Quantitative Semiautomated Image Analysis of Synovial Biopsies Studied Using a Novel High-Plex Immunofluorescence Platform
  • Abstract Number: 1788

    Manganese-associated Single-nucleotide Polymorphisms are Associated with Radiographic Knee Osteoarthritis: The Johnston County Osteoarthritis Project
  • Abstract Number: 1789

    Spatial Analysis of Advanced Osteoarthritis Synovial Tissue
  • Abstract Number: 1790

    Targeted Ablation of Knee-innervating Nociceptors Attenuates Pain and Cartilage Degeneration in Experimental Osteoarthritis
  • « Previous Page
  • 1
  • …
  • 119
  • 120
  • 121
  • 122
  • 123
  • …
  • 182
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology